While further research needs to be performed, these results suggest that SGB could be a singular treatment option for patients suffering from both PTSD and chronic pain, potentially simplifying treatment regimens for complex cases involving CS syndromes. The gene discussed is GPC3; the disease is post-traumatic stress disorder.